Clinical trial

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

NCT00141726

Study summary

ClinicalTrials.gov

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Etanercept Normalized identity: etanercept View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-10-01

PhasePHASE2

Conditions

Lung Injury, Acutecandidate · MONDO: acute lung injury

Respiratory Distress Syndrome, Adultverified · MONDO: adult acute respiratory distress syndrome

Bronchiolitis Obliteransunresolved

Interventions

EtanerceptDRUG · verified · RxNorm: etanercept

Sponsors & collaborators

University of Michigan Rogel Cancer Centerlead sponsor

Mapped research locations

Ann ArborMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00141726 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.